ClearPoint Neuro (CLPT) Projected to Post Quarterly Earnings on Tuesday

Key Points

• ClearPoint Neuro is set to announce its Q2 2025 earnings on August 12th, with expected losses of ($0.20) per share and revenues of $9.20 million.
• In its last earnings report, the company posted a loss of ($0.22) per share, missing estimates, while revenue of $8.49 million exceeded expectations.
• Analysts have issued mixed ratings for ClearPoint Neuro, with Stifel Nicolaus upgrading the stock to a "buy" and Wall Street Zen downgrading it to "sell."

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) is expected to be announcing its Q2 2025 earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $9.20 million for the quarter. ClearPoint Neuro has set its FY 2025 guidance at EPS.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.07). The firm had revenue of $8.49 million during the quarter, compared to analysts' expectations of $8.21 million. ClearPoint Neuro had a negative net margin of 64.51% and a negative return on equity of 78.09%. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Stock Performance

Shares of ClearPoint Neuro stock traded down $0.10 during trading on Friday, reaching $10.82. The company had a trading volume of 255,179 shares, compared to its average volume of 393,020. The company has a market cap of $302.85 million, a price-to-earnings ratio of -14.24 and a beta of 0.85. The firm's fifty day moving average is $11.58 and its 200-day moving average is $13.30. ClearPoint Neuro has a fifty-two week low of $8.64 and a fifty-two week high of $19.22.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus upped their target price on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Wall Street Zen lowered shares of ClearPoint Neuro from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th.

Insider Activity at ClearPoint Neuro

In other ClearPoint Neuro news, Director Timothy T. Richards sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $13.28, for a total value of $132,800.00. Following the sale, the director owned 77,381 shares in the company, valued at approximately $1,027,619.68. This trade represents a 11.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Joseph Burnett sold 21,247 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $13.29, for a total transaction of $282,372.63. Following the completion of the sale, the chief executive officer owned 243,522 shares in the company, valued at $3,236,407.38. The trade was a 8.02% decrease in their position. The disclosure for this sale can be found here. 6.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in ClearPoint Neuro stock. Goldman Sachs Group Inc. increased its stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 98.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 257,871 shares of the company's stock after acquiring an additional 127,823 shares during the period. Goldman Sachs Group Inc. owned approximately 0.92% of ClearPoint Neuro worth $3,066,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 30.08% of the company's stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.